Summary: New Oral Medication for Type 2 Diabetes
Patient Inclusion/Exclusion Criteria
· Must be 21-65 years old
· Must have type 2 diabetes
· Must never have taken more than 1 oral medication for treatment of diabetes
· Must never have taken insulin, Rezulin, Avandia or Actos
This is a 14-week study that evaluates the glucose-lowering and lipid-lowering effectiveness of a new oral medication (investigational) in subjects with type 2 diabetes.
Contact:
Endocrine Research Team
SUNY Upstate Medical University
Syracuse, NY
Telephone: 315-464-9006/9008

Summary: Do you have… Type 2 Diabetes?
If you have Type 2 diabetes, you may qualify for a research study with an investigational medication for the treatment of Type 2 Diabetes.
Qualifying participants will receive free study-related:
· Physical examinations
· Electrocardiogram
· Office visits
· Study medications
· Laboratory tests
· Transportation, if needed
· Blood Glucose Meter
· Testing supplies
Contact:
Pivotal Research Centers, LLC
Located in: Mesa, AZ
Telephone: 1-800-574-8307
Or 623-977-1234
Email: studies@pivotalresearch.com

Summary: Diabetes? You may qualify for a Clinical Research Study involving an investigational medicine
· 25-75 years of age
· On Meformin or Glucophage
This is a 13-week study, requiring you to say overnight in the facility on 2 separate occasions and make 6 outpatient visits. Compensation up to $650 for time and travel.
Contact:
Orlando Research Center
5055 South Orange Avenue
Orlando, FL 32909
Telephone: 407-240-7878

Summary: Medical center studying pre-diabetes
Twin Cities Clinical Research is taking part in a drug research study to assess the ability of medication to delay the progression to diabetes.
Participants will:
· Receive physical evaluation at no cost
· Receive investigational medication or placebo at no cost
· Be considered for long-term treatment at no cost
If you or someone close to you:
· Is at risk for, or diagnosed with cardiovascular disease
· Is over the age of 50 (male or female)
Contact:
Jane McGinley, RN CCRC, Twin Cities Clinical Research
3585 Lexington Avenue N, Suite 350
Arden Hills, MN 55126
Telephone: 651-765-9191
Fax: 651-765-9229
Email: twincitiesclinic@qwest.net

Summary: Study of Diabetes Prevention African Americans Needed for Diabetes Prevention Study
African Americans are twice as likely as other populations to develop diabetes. Dr. Joseph Aloi at the University of Virginia is looking for African Americans who are at risk for developing diabetes to participate in a diabetes prevention research study. Diabetes risk factors include family history of diabetes or early heart disease, high blood pressure, high cholesterol, current or past cigarette smoking, overweight, and previous cardiovascular events such as stroke or heart attack.
Candidates interested in this diabetes prevention research must be non-diabetic, at least 50 years old and have some of the common risk factors for developing diabetes. All study related care is provided at no charge to those who take part including doctor visits, physical examinations, laboratory tests, diet and exercise counseling, and study medication. Financial compensation is also provided.
Contact:
Joseph A Aloi, MD, University of Virginia, School of Medicine
General Medicine & Geriatrics, Internal Medicine
Box 800518
Charlottesville, VA 22908
Telephone: 540-672-5500
Email: jaa3s@virginia.edu

Summary: Novartis Pharmaceuticals Corporation is conducting a 24 week clinical research study for males and females between the ages of 18 and 80 years old with Type 2 Diabetes who are inadequately controlled with insulin
The purpose of this 24 week clinical research study is to assess the safety and effectiveness of an add on investigational drug in patients with Type 2 Diabetes treated with insulin.
Participants must meet all of the following criteria:
· Males and females between the ages of 18 and 80 years old
· Willing to use an approved method of birth control (if required)
· Have a diagnosis of Type 2 Diabetes
· Previously treated with insulin for at least 3 months and have been on a minimum dose of 30 units of insulin per day for 4 weeks before entering the study
· Agree to maintain prior diet and exercise program
You CANNOT participate if you:
· Pregnant or breastfeeding
· Have a history of Type 1 Diabetes
· Are receiving treatment with an insulin pump
· Have a serious medical or surgical conditions
· Have liver disease
· Have taken oral antidiabetic medication within 3 months before entering the study
· Are taking growth hormones
· Have leukemia or lymphoma
· Have a history of active substance abuse (including alcohol) within the past 2 years
Contact:
Nada Klanjac, Study Coordinator
Monteagle Medical Center
1580 Valencia St., Suite 504
San Francisco, CA 94110
Telephone: 415-648-7622
Fax: 415-648-6805

Summary: This clinical research study aims to assess the safety and effectiveness of adding an investigational study medication to the Food and Drug Administration (FDA) approved drug Pioglitazone (Actos®) for lowering blood sugar levels in people with Type 2 Diabetes.
A 24 week research study is being conducted for males and females between the ages of 18-80 years old that cannot control their Type 2 Diabetes with Pioglitazone (Actos®) tablets or Rosiglitazone (Avandia®) along with diet and exercise.
Participants must meet all of the following criteria:
· Males and females between the ages of 18 and 80 years old
· Have a diagnosis of type 2 diabetes
· Taking Rosiglitazone (Avandia®) or Pioglitazone (Actos®) for 3 months before entering the study
· Agree to maintain current diet and exercise habits
· Willing to take an approved method of birth control if required
Participants CANNOT meet any of the following criteria:
· Diagnosis of type 1 diabetes
· Pregnant or breastfeeding
· Serious medical or surgical condition
· Leukemia or lymphoma
· Liver disease
· Taking growth hormones
Contact:
Isabel Estavez, Study Coordinator
Z & Z Medical Associates
5959 Harry Hines Blvd., Suite 904
Dallas, TX 75235
Telephone: 214-879-7800
Fax: 214-879-7808

To find clinical trials in your area, go to: http://www.centerwatch.com/search.asp